NEUROCENTRX PHARMA LIMITED

Active Edinburgh

Research and experimental development on biotechnology

1 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
N

NEUROCENTRX PHARMA LIMITED

Research and experimental development on biotechnology

Founded 18 Jul 2013 Active Edinburgh, Scotland 1 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
Accounts Submitted 27 Oct 2025 Next due 30 Sept 2026 3 months remaining
Confirmation Submitted 21 May 2026 Next due 4 Jun 2027 12 months remaining
Net assets £-750K £430K 2024 year on year
Total assets £103K £95K 2024 year on year
Total Liabilities £853K £335K 2024 year on year
Charges 1
1 outstanding

Contact & Details

Contact

Registered Address

Level 5, 9 Haymarket Square Edinburgh EH3 8RY Scotland

Telephone

0800 000 0000

Website

www.example.com

Full company profile for NEUROCENTRX PHARMA LIMITED (SC454814), an active life sciences and medical technology company based in Edinburgh, Scotland. Incorporated 18 Jul 2013. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Nov → 31 Oct 2024
Type total-exemption-full
Next accounts 31 Dec 2025
Due by 30 Sept 2026 3 months remaining

Net Assets, Total Assets & Total Liabilities (2014–2024)

Cash in Bank

£34.43k

Decreased by £95.40k (-73%)

Net Assets

-£750.24k

Decreased by £430.18k (-134%)

Total Liabilities

£853.25k

Increased by £335.02k (+65%)

Turnover

N/A

Employees

1

Decreased by 1 (-50%)

Debt Ratio

828%

Increased by 566 (+216%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
31 Oct Year End
2023
31 Oct Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 7

Investors (7)

Investor NameInvestor SinceParticipating Rounds
Investor 7Jul 2013Unknown/Other
Investor 1Mar 2014Seed, Growth/Late Stage
Investor 2May 2022Growth/Late Stage

Share Capital

Share Capital

Share allotments and capital structure

7 Allotments 3,171,146 Shares £104.33m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
24 Oct 202587,948£101.49m£1k
27 Sept 2024557,362£548k£0.984
27 Sept 2024557,362£548k£0.984
27 Sept 2024557,362£548k£0.984
27 Sept 2024557,362£548k£0.984

Officers

Officers

2 active 1 resigned
Status
Duncan, GraemeDirectorBritishScotland5116 Jun 2023Active
Mfmac Secretaries LimitedCorporate-secretaryUnited KingdomUnknown24 Apr 2017Active

Shareholders

Shareholders (45)

Scottish Enterprise
27.4%
2,189,565
Neo Kuma
10.6%
848,509

Persons with Significant Control

Persons with Significant Control (1)

1 Active 2 Ceased

Scottish Enterprise

Unknown

Active
Notified 6 Apr 2016
Nature of Control
  • Ownership Of Shares 25 To 50 Percent,voting Rights 25 To 50 Percent

Equity Gap Limited

Ceased 12 Nov 2019

Ceased

Fraser Stuart Lusty

Ceased 6 Apr 2016

Ceased

Group Structure

Group Structure

No group structure identified

Charges

Charges

1 outstanding

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
21 May 2026Confirmation StatementConfirmation statement made on 21 May 2026 with updates
27 Oct 2025CapitalAllotment of shares (GBP 79.7011) on 24 Oct 2025
27 Oct 2025AccountsAnnual accounts made up to 31 Oct 2025
7 Oct 2025ResolutionResolutions
7 Oct 2025IncorporationMemorandum Articles
21 May 2026 Confirmation Statement

Confirmation statement made on 21 May 2026 with updates

27 Oct 2025 Capital

Allotment of shares (GBP 79.7011) on 24 Oct 2025

27 Oct 2025 Accounts

Annual accounts made up to 31 Oct 2025

7 Oct 2025 Resolution

Resolutions

7 Oct 2025 Incorporation

Memorandum Articles

Recent Activity

Latest Activity

Confirmation statement made on 21 May 2026 with updates

2 weeks ago on 21 May 2026

Allotment of shares (GBP 79.7011) on 24 Oct 2025

7 months ago on 27 Oct 2025

Annual accounts made up to 31 Oct 2025

7 months ago on 27 Oct 2025

Resolutions

8 months ago on 7 Oct 2025

Memorandum Articles

8 months ago on 7 Oct 2025